Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials signals ...
CRAFT-WHF Phase 2 trial of COR-1167 initiated in patients with worsening heart failure Phase 1 trial of COR-1389 ongoing in subjects with obesity Paris, France, July 21, 2025 – Corteria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback